Versity Assessment of Medications and Current Practices

Total Page:16

File Type:pdf, Size:1020Kb

Versity Assessment of Medications and Current Practices 218 REVIEW Treatment of acute diarrhoea : update of guidelines based on a critical interuni- versity assessment of medications and current practices D. Urbain1, J. Belaiche2, M. De Vos3, R. Fiasse4, M. Hiele5, S. Huijghebaert6, F. Jacobs7, H. Malonne8, P. Speelman9, A. Van Gompel10, A. Van Gossum11, E. Van Wijngaerden12 (1) Department of Gastroenterology, Free University of Brussels (VUB) ; (2) Department of Gastroenterology, University Hospital Medical Center (CHU) Sart-Tilman, Liège ; (3) Department of Gastroenterology, Gent University (RUG) ; (4) Department of Gastroenterology, Catholic University of Louvain (UCL), Brussels ; (5) Catholic University of Leuven (KUL) ; (6) PhD. Pharm., Pharmaceutical Sciences Consultant, La Hulpe ; (7) Department of Infectious Diseases, Free University of Brussels (ULB) ; (8) Department of Pharmacology, Free University of Brussels (ULB) ; (9) Department of Infectious Diseases, AMC, Amsterdam (Netherlands) ; (10) Department of Gastroenterology, Institute of Tropical Medicine, Antwerp ; (11) Department of Gastroenterology, Free University of Brussels (ULB) ; (12) Department of Infectious Diseases, Catholic University of Leuven (KUL). Abstract approach is justified in children, in whom the risk-bene- fit of drugs in general is uncertain, and in adults suffer- Further to a thorough analysis of the problem of acute diar- ing a short-lasting bout of diarrhoea for less than rhoea and the therapeutic options, recommendations were defined following a multidisciplinary approach. These guidelines take into 24 hours. It is more difficult to understand in adults with account the reality of frequent self-medication. They further differ disabling symptoms. Acute diarrhoea presents with as a function of age (children, primarily treated by ORS and for physically impairing symptoms such as cramping, whom self-medication is not advised versus adults who can self- medicate), symptoms (uncomplicated diarrhoea versus dysentery) abdominal pain or pressure and urgency. Adult patients and location where the diarrhoea is contracted (at home or when moreover experience social dysfunction and fear social travelling). (Acta gastroenterol. belg., 2003, 66, 218-226). embarrassment. There are thus reasons to help the Key words : acute diarrhoea, treatment, guidelines, oral rehydration, patient, if symptoms are impairing. When compared to diet, probiotic, loperamide, antibiotic. headache, another common ailment, for which it is socially and medically accepted to provide immediate symptom relief, diarrhoea carries a heavy social stigma. Introduction A reason to withhold medication has been the opinion that diarrhoea functions as a defence mechanism to Acute diarrhoea is defined as a sudden abnormal eliminate pathogens and therefore should not be treated increase in liquid consistency and frequency of bowel with an antidiarrhoeal that will modify intestinal secre- movements. It is usually self-limiting but it can also tions and motility (10,11). The data used to support this result in serious inconvenience to the patient and in the notion are scarce (12) and have recently been judged case of a child, be a major concern for parents. An unconvincing (1).Also our panel could not confirm such effective and reassuring approach to the problem is rationale after in-depth analysis of these data, consider- desirable (1). Guidelines, however, frequently propose ation of the different mechanisms involved in diarrhoea divergent recommendations, with a sole exception : the (13,14), and evaluation of clinical studies with the position of oral rehydration solutions (ORS) as the pri- antidiarrhoeal loperamide in acute infectious diarrhoea mary and essential treatment in infant diarrhoea. This (15-19). The current therapeutic options for acute diar- recommendation is supported both by the World Health rhoea were reviewed by this panel, and their risk-benefit Organisation (WHO) and paediatric associations world- profile, resulting from published clinical evidence, prod- wide, such as the American Association of Paediatrics uct labelling and current medical expertise, is sum- (AAP) and the European Society of Paediatric marised in the tables of this publication. Gastroenterology, Hepatology and Nutrition Patients with diarrhoea very often treat themselves. (ESPGHAN) (2-6). Two thirds of the medications for diarrhoea in Belgium Discrepancies in recommendations mainly apply to are dispensed without a prescription (20). Therefore it is dietary measures, need to medicate and therapeutic important that the risk groups for which medical advice options. They may arise from different risk-benefit inter- is mandatory are properly defined. Education of the self- pretations and perceptions. With respect to the dietary medicating adult patient and clear instructions to the car- management of diarrhoea, fasting, diets and special milk ing parent are warranted. In view of differences in risks, formula are still popular, despite the evidence in paedi- tolerability and efficacy of therapeutic approaches atric diarrhoea that early resumption of normal feeding leads to faster recovery and the latter recommendation by the WHO, AAP and ESPGHAN (4-7). Further, med- ———————— ication for diarrhoea is often discouraged and postponed Correspondence to : Prof. Dr. D. Urbain, Department of Gastroenterology, VUB, until after 2 days of diarrhoea suffering (8,9). Such an Laerbeeklaan 101, B-1090 Brussels. E-mail : [email protected]. Acta Gastro-Enterologica Belgica, Vol. LXVI, July-September 2003 Acute diarrhoea : treatment and update of guidelines 219 Table 1. — Signs of dehydration General Signs of severe dehydration > 10% in babies – A general weak condition (difficult standing on feet) – High temperature, but absence of sweating – Dry mucous membrane – Crying without tears – Confusion – Cessation of urination – Reduced consciousness or drowsiness – Weakness and decreased alertness – Reduced skin turgor (sticky skin, having lost its tension when taken between thumb and forefinger) between children and adults, their respective manage- An excessive amount of salt can lead to hyperna- ment is discussed separately in this article. Management tremia (a sensation of thirst, drowsiness, weakness, specific to the elderly is not discussed. irritability developing into muscular contractions, epilepsy and coma). The preparation of homemade I. Treatment of children ORS is therefore not recommended unless in emer- gency situations, for want of something better. If ORS The term ‘children’ is defined here as the age group powder in line with the recommendations of the from 0 to 4 years. This age group is extremely suscepti- WHO/paediatric associations, is not commercially ble to dehydration (Table 1). The infant group up to age available, ORS can be prepared by mixing 20 g glu- six months, in particular, requires special attention. cose or 40 g saccharose (8 pieces of sugar of 5 g) with 3 Older children (above 4 years) and adolescents are less 3.5 g NaCl (salt : /4 of a coffee spoon) and 1.5 g susceptible to dehydration. Treatment in children there- potassium chloride (a glass of orange juice or fore will focus in the first place on oral rehydra- 2 bananas) for 1 litre of water (to be cooked in tion (2,3). The rapid reestablishment of normal feeding cholera-endemic areas). However, such preparation has also been found to play an important role in the should not be routinely recommended. Commercial process of recovery (4,5). ORS are better in quality and entail fewer risks for the infant. ORS are also more efficient in hydrating the ORS infant than commercially available sugar-containing beverages, such as Coca-Cola® or soft drinks (rela- – Various ORS are available in pharmacies. They con- tively few electrolytes, much sugar) and rice water tain an optimal ratio of sugar (glucose) and elec- (too few carbomonohydrates). trolytes (salts) in order to stimulate the sodium-glu- cose co-transport in the small intestine and the resul- tant absorption of water. Some ORS contain also General recommendations for the physicians and amino acids stimulating the amino acid-glucose co- parents transport. These solutions, taken orally, are as effec- Doctors can best give following advice to parents : tive as parenteral infusions in rehydrating the body during secretory diarrhoea. All commercial ORS – It is important to monitor the child closely. Infants powders are very similar in electrolyte-sugar compo- can soon get better, but their condition can also dete- sition and osmolarity, some are rice-based (21,22). riorate rapidly. Especially the baby who vomits and Soparyx®, for instance, contains rice powder, so that frequently passes watery stools, should raise concerns it has a slightly higher calorific value and a lower because of the high risk of rapid dehydration : 80% of osmolarity than the other ORS. It is however not the infant’s body weight consists of fluid ; further- advised under the age of one year, because it contains more, the renal capacity to concentrate urine is much aspartame, an artificial sweetener with allergizing lower. It is recommended that the physician closely potential. In general, ORS are hypocaloric : it is thus monitors the course of the disease in babies with important to encourage parents to resume the child’s severe diarrhoea (e.g. with vomiting and 8-10 bowel normal feeds as soon as possible (2,3). movements). Such infants, or infants exhibiting slight – It is important to dissolve the ORS powder in the cor- signs of dehydration on initial examination, are best
Recommended publications
  • Susceptibility of Archaea to Antimicrobial Agents: Applications to Clinical Microbiology
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW 10.1111/j.1469-0691.2012.03913.x Susceptibility of archaea to antimicrobial agents: applications to clinical microbiology S. Khelaifia and M. Drancourt Unite´ de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UMR CNRS 6236 IRD 3R198, Me´diterrane´e Infection, Faculte´ de Me´decine, Aix-marseille-Universite´, Marseille, France Abstract We herein review the state of knowledge regarding the in vitro and in vivo susceptibility of archaea to antimicrobial agents, including some new molecules. Indeed, some archaea colonizing the human microbiota have been implicated in diseases such as periodontopathy. Archaea are characterized by their broad-spectrum resistance to antimicrobial agents. In particular, their cell wall lacks peptidoglycan, making them resistant to antimicrobial agents interfering with peptidoglycan biosynthesis. Archaea are, however, susceptible to the pro- tein synthesis inhibitor fusidic acid and imidazole derivatives. Also, squalamine, an antimicrobial agent acting on the cell wall, proved effective against human methanogenic archaea. In vitro susceptibility data could be used to design protocols for the decontamination of complex microbiota and the selective isolation of archaea in anaerobic culture. Keywords: Antimicrobial agent, archaea, methanogenic archaea, microbiota, susceptibility testing Article published online: 23 May 2012 Clin Microbiol Infect 2012; 18: 841–848 Corresponding author: M. Drancourt, Unite´ des Rickettsies, Fa- culte´ de Me´decine, 27, Boulevard Jean Moulin-Cedex 5, France E-mail: [email protected] Methanogenic archaea (herein referred to as methano- Introduction gens) are the sole organisms producing methane from H2 +CO2 [6].
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Leishmania (Leishmania) Infantum Promastigotes and Intracellular Amastigotes
    Experimental Parasitology 163 (2016) 68e75 Contents lists available at ScienceDirect Experimental Parasitology journal homepage: www.elsevier.com/locate/yexpr Full length article Effects of nitro-heterocyclic derivatives against Leishmania (Leishmania) infantum promastigotes and intracellular amastigotes Simone Carolina Soares Petri e Silva a, Fanny Palace-Berl b, Leoberto Costa Tavares b, * Sandra Regina Castro Soares a, Jose Angelo Lauletta Lindoso a, c, d, a Laboratorio de Soroepidemiologia e Imunobiologia, do Instituto de Medicina Tropical da, Universidade de Sao~ Paulo, Brazil b Laboratorio de Planejamento de Desenvolvimento de Farmacos, Faculdade de Ci^encias Farmac^euticas da, Universidade de Sao~ Paulo, Brazil c Instituto de Infectologia Emilio Ribas-Secretaria de Estado da Saúde de Sao~ Paulo, Brazil d Laboratorio de Soroepidemiologia (LIM 38 HC-FMUSP), Brazil graphical abstract article info abstract Article history: Leishmaniasis is an overlooked tropical disease affecting approximately 1 million people in several Received 19 May 2015 countries. Clinical manifestation depends on the interaction between Leishmania and the host's immune Received in revised form response. Currently available treatment options for leishmaniasis are limited and induce severe side 19 October 2015 effects. In this research, we tested nitro-heterocyclic compounds (BSF series) as a new alternative against Accepted 15 January 2016 Leishmania. Its activity was measured in Leishmania (Leishmania) infantum promastigotes and intracel- Available online 18 January 2016 lular amastigotes using MTT colorimetric assay. Additionally, we assessed the phosphatidylserine exposure by promastigotes, measured by flow cytometry, as well as nitric oxide production, measured by Keywords: Leishmania (L.) infantum Griess' method. The nitro-heterocyclic compounds (BSF series) showed activity against L.
    [Show full text]
  • Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
    IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 1/89 PROTOCOL TITLE: EFFICACY OF DIOSMECTITE (SMECTA®) IN THE SYMPTOMATIC TREATMENT OF ACUTE DIARRHOEA IN ADULTS. A MULTICENTRE, RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL GROUPS STUDY STUDY PROTOCOL STUDY number: F-FR-00250-105 (Diosmectite- BN 00250) EudraCT number: n° 2015-001138-10 Final Version (with Amendment No. 4): 07 January 2019 Sponsor’s Medically Responsible Person: Study Sponsor: PPD Ipsen Pharma SAS PPD 65 quai Georges Gorse Ipsen Pharma SAS 92100 Boulogne-Billancourt, France 65 quai Georges Gorse Tel: PPD 92100 Boulogne-Billancourt, France Fax: PPD Tel: PPD Fax: PPD Monitoring Office: and/or CRO Co-ordinating Investigator: PPD PPD PPD Délégation à la Recherche Ipsen Pharma SAS Centre Hospitalier Régional Universitaire 65 quai Georges Gorse de Lille 92100 Boulogne-Billancourt, France 2, avenue Oscar Lambret, Tel: PPD 59037 Lille, France Cedex Fax: PPD Tel: PPD Fax: PPD Pharmacovigilance/Emergency Contact: PPD Ipsen Innovation, ZI de Courtaboeuf - 5 avenue du Canada - 91940 Les Ulis - France Tel: PPD Tel: PPD – PPD For SAEs reporting: Fax: PPD Email: PPD Persons supplied with this information must understand that it is strictly confidential. Information contained herein cannot be disclosed, submitted for publication or used for any purpose other than that contemplated herein without the sponsor’s prior written authorisation. IPSEN GROUP F-FR-00250-105 CONFIDENTIAL PROTOCOL: FINAL (WITH AMENDMENT NO. 4): 07 JANUARY 2019 PAGE 2/89 INVESTIGATOR’S AGREEMENT Investigator Agreement and Signature: I have read and agree to Protocol F-FR-00250-105 entitled Efficacy of the diosmectite (Smecta®) in the symptomatic treatment of acute diarrhoea in adults.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: a Review
    chemosensors Review Advances in Antimicrobial Resistance Monitoring Using Sensors and Biosensors: A Review Eduardo C. Reynoso 1 , Serena Laschi 2, Ilaria Palchetti 3,* and Eduardo Torres 1,4 1 Ciencias Ambientales, Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico; [email protected] (E.C.R.); [email protected] (E.T.) 2 Nanobiosens Join Lab, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Firenze, Italy; [email protected] 3 Dipartimento di Chimica, Università degli Studi di Firenze, Via della Lastruccia 3, 50019 Sesto Fiorentino, Italy 4 Centro de Quìmica, Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico * Correspondence: ilaria.palchetti@unifi.it Abstract: The indiscriminate use and mismanagement of antibiotics over the last eight decades have led to one of the main challenges humanity will have to face in the next twenty years in terms of public health and economy, i.e., antimicrobial resistance. One of the key approaches to tackling an- timicrobial resistance is clinical, livestock, and environmental surveillance applying methods capable of effectively identifying antimicrobial non-susceptibility as well as genes that promote resistance. Current clinical laboratory practices involve conventional culture-based antibiotic susceptibility testing (AST) methods, taking over 24 h to find out which medication should be prescribed to treat the infection. Although there are techniques that provide rapid resistance detection, it is necessary to have new tools that are easy to operate, are robust, sensitive, specific, and inexpensive. Chemical sensors and biosensors are devices that could have the necessary characteristics for the rapid diag- Citation: Reynoso, E.C.; Laschi, S.; nosis of resistant microorganisms and could provide crucial information on the choice of antibiotic Palchetti, I.; Torres, E.
    [Show full text]
  • PRAC Draft Agenda of Meeting 14-17 April 2020
    14 April 2020 EMA/PRAC/132684/2020 Human Division Pharmacovigilance Risk Assessment Committee (PRAC) Draft agenda for the meeting on 14-17 April 2020 Chair: Sabine Straus – Vice-Chair: Martin Huber 14 April 2020, 10:30 – 19:30, via teleconference 15 April 2020, 08:30 – 19:30, via teleconference 16 April 2020, 08:30 – 19:30, via teleconference 17 April 2020, 08:30 – 16:00, via teleconference Organisational, regulatory and methodological matters (ORGAM) 30 April 2020, 09:00-12:00, via teleconference Health and safety information In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting. Disclaimers Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also change during the course of the review. Additional details on some of these procedures will be published in the PRAC meeting highlights once the procedures are finalised. Of note, this agenda is a working document primarily designed for PRAC members and the work the Committee undertakes. Note on access to documents Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on- going procedures for which a final decision has not yet been adopted.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,095,545 B2 Borody (45) Date of Patent: * Aug
    US009095545B2 (12) United States Patent (10) Patent No.: US 9,095,545 B2 Borody (45) Date of Patent: * Aug. 4, 2015 (54) METHODS FORTREATING 2004/0106590 A1 6/2004 Eisenstein GASTRONTESTINAL DISORDERS 2004/0126318 A1* 7/2004 Ehrenpreis..................... 4249.1 ASSOCIATED WITH PARKINSONS DISEASE, 3.99. A 39: Rayishuila et al. AUTISM, DIABETIC GASTROPARESIS (Continued) (71) Applicant: Thomas Julius Borody, Sydney (AU) FOREIGN PATENT DOCUMENTS (72) Inventor: Thomas Julius Borody, Sydney (AU) WO O3O37310 5, 2003 (*) Notice: Subject to any disclaimer, the term of this WO 2007O22255 2, 2007 patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 0 days. This patent is Subject to a terminal dis OTHER PUBLICATIONS claimer. Andrew, Peter J. et al., “Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis”, Euro J. Gast Hep, 1992, (21) Appl. No.: 14/324,924 4:245-7. (22) Filed: Jul. 7, 2014 (Continued) (65) Prior Publication Data Primary Examiner — Jeffrey E. Russel US 2014/O364373 A1 Dec. 11, 2014 (74) Attorney, Agent, or Firm — Gregory P. Einhorn; Greer, Related U.S. Application Data Burns & Crain Ltd. (63) Continuation of application No. 13/499.270, filed as application No. PCT/AU2010/001410 on Oct. 22, (57) ABSTRACT 2010, now Pat. No. 8,772,242. There is disclosed herein a composition for treating gas (30) Foreign Application Priority Data trointestinal or neurological disorders, constipation, func tional constipation, irritable bowel syndrome, diverticulitis, Oct. 26, 2009 (AU) ................................ 2009905229 travelers’ diarrhea, chronic idiopathic nausea, IBD-associ ated constipation and diarrhea, pseudo-obstruction, diabetic (51) Int.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Systematic Review of Loperamide
    Travel Medicine and Infectious Disease (2016) 14, 299e312 Available online at www.sciencedirect.com ScienceDirect journal homepage: www.elsevierhealth.com/journals/tmid REVIEW Systematic review of loperamide: No proof of antibiotics being superior to loperamide in treatment of mild/moderate travellers’ diarrhoea Tinja La¨¨averi a,1, Jesper Sterne b,1, Lars Rombo b,c, Anu Kantele a,c,d,* a Inflammation Center, Division of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, POB 348, FIN-00029 HUS, Finland b Centre for Clinical Research, So¨rmland County Council, Eskilstuna and University of Uppsala, SE 631 88 Eskilstuna, Sweden c Karolinska Institutet, Department of Medicine/Solna, Unit for Infectious Diseases, SE 17176 Stockholm, Sweden d Department of Medicine, University of Helsinki, Finland Received 9 May 2016; received in revised form 19 June 2016; accepted 20 June 2016 Available online 27 June 2016 KEYWORDS Summary Looking at the worldwide emergency of antimicrobial resistance, international trav- Adverse drug event; ellers appear to have a central role in spreading the bacteria across the globe. Travellers’ diar- Safety; rhoea (TD) is the most common disease encountered by visitors to the (sub)tropics. Both TD and Antibiotics; its treatment with antibiotics have proved significant independent risk factors of colonization by Antidiarrhoeals; resistant intestinal bacteria while travelling. Travellers should therefore be given preventive Antibiotic resistance advice regarding TD and cautioned about taking antibiotics: mild or moderate TD does not require antibiotics. Logical alternatives are medications with effects on gastrointestinal func- tion, such as loperamide. The present review explores literature on loperamide in treating TD. Adhering to manufacturer’s dosage recommendations, loperamide offers a safe and effective alternative for relieving mild and moderate symptoms.
    [Show full text]
  • Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children
    Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children Recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics (This guideline was simultaneously published in The Pediatric Infectious Disease Journal on November 6, 2013.) Prepared by George K. Siberry MD, MPH, Executive Edward Handelsman MD;1,§ Secretary;1 Lynne M. Mofenson MD;1 Mark J. Abzug MD, Co-Chair;2 Steve Nesheim MD;5 Sharon Nachman MD, Co-Chair;3 and the Panel on Opportunistic Infections in HIV- Michael T. Brady MD;4 Exposed and HIV-Infected Children* Kenneth L. Dominguez MD, MPH;5 1National Institutes of Health, Bethesda, Maryland 2University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado 3State University of New York at Stony Brook, Stony Brook, New York 4Nationwide Children’s Hospital, Columbus, Ohio 5Centers for Disease Control and Prevention, Atlanta, Georgia * Panel member authors (in alphabetical order): Debika Bhattacharya, MD; Beverly Bohannon, MS, RN; Diana Clarke, Pharm. D.; Kathryn M. Edwards, MD; Jennifer C. Esbenshade, MD, MPH; Patricia Flynn, MD; Aditya Gaur, MD; Francis Gigliotti, MD; Gail Harrison, MD; Charlotte Victoria Hobbs, MD; David Kimberlin, MD; Martin B. Kleiman, MD; Emilia H. Koumans, MD, MPH; Andrew Kroger, MD, MPH; Myron J. Levin. MD; Cara L. Mack, MD; Ben J. Marais, MD; Gabriela Maron, MD; James McAuley, MD, MPH; Heather J. Menzies, MD, MPH; Anna-Barbara Moscicki, MD; Michael R. Narkewicz, MD; Richard Rutstein, MD; Jane Seward, MBBS, MPH; Masako Shimamura, MD; William J.
    [Show full text]